Clinical trials: Type II Diabetic Patients With Nephropathy
Type2 Diabetes, Diabetic Kidney Disease
Efficacy of a High-intensity Physical Activity Program on Renal Function in High Risk Patients With Type 2 Diabetes
Type 2 diabetes is a chronic condition whose prevalence is increasing globally. Kidney disease is a key complication of diabetes and is among the most common cause of end-stage renal disease, requiring renal replacement therapy.
- Trial name
- ACTIDIANE (NCT03184662)
- Testing
- HIPA, Counseling PA
- Where
- 20 sites in Belgium, France
- Volunteers
- 178 people
- Sponsor
- Poitiers University Hospital
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
NADPH oxidase enzymes (NOX) have been implicated in the development of several diabetic complications including diabetic nephropathy. GKT137831 is the first in class NOX1/4 inhibitor.
- Trial name
- NCT02010242
- Testing
- GKT137831
- Where
- 48 sites in United States, Australia and 4 more
- Volunteers
- 136 people
- Sponsor
- Calliditas Therapeutics AB
Diabetes Mellitus, Diabetic Nephropathy
Study of Genome-associated Mechanisms of Diabetic Nephropathy and Evaluation of Nephroprotective Therapy in Patients With Type 2 Diabetes Mellitus in the Kazakh Population
The incidence of diabetes remains a serious global health issue, demanding close attention and the development of comprehensive strategies for prevention, early diagnosis, and effective treatment .
- Trial name
- NCT07038213
- Testing
- glycation genes, beta 2 microglobulin
- Where
- Kazakhstan
- Volunteers
- 100 people
- Sponsor
- Astana Medical University
Diabetes Mellitus, Type 2, Diabetic Kidney Disease
Renohemodynamic Effects of Combined empagliflOzin and LosARtan
Worldwide, diabetic kidney disease (DKD) is the most common cause of chronic and end stage kidney disease. In parallel with the ever-increasing rates of obesity and type 2 diabetes (T2D), the incidence of DKD is expected to…
- Trial name
- RECOLAR (NCT04238702)
- Testing
- Empagliflozin 10 MG, Losartan 50Mg Tab
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- Amsterdam UMC, location VUmc
Type 2 Diabetic Nephropathy
Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients
This study aims to evaluate the efficacy and safety of DWP16001 in type 2 diabetic nephropathy with moderate renal impairment patients (CKD stage 3)
- Trial name
- NCT06606093
- Testing
- DWP16001 0.3mg
- Where
- South Korea
- Volunteers
- 348 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Type 2 DM /Diabetic Nephropathy
CRP to Serum Albumin Ratio in Type 2 DM é Diabetic Nephropathy
we aimed to compare C-reactive protein to serum albumin ( CAR) level of the T2DM patients with DN to those T2DM without DN
- Trial name
- NCT05681286
- Volunteers
- 70 people
- Sponsor
- Assiut University
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Serum 1,25-dihydroxyvitamin D Levels in Type 2 Diabetes Mellitus Patients With Different Levels of Albuminuria
Diabetic nephropathy(DN)is a major microvascular complication of diabetes.Renal injury may be presented with the characteristics of albuminuria, and its main pathological change is glomerular sclerosis.
- Trial name
- DM (NCT01845870)
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Tianjin Medical University General Hospital
Chronic Kidney Diseases
Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria
The aim of this study is to test the hypothesis that the effects on albuminuria of combination treatment with the endothelin receptor antagonist zibotentan and SGLT2i dapagliflozin are complimentary and additive while the fluid…
- Trial name
- ZODIAC (NCT05570305)
- Testing
- Zibotentan, Dapagliflozin, Dapagliflozin and Zibotentan
- Where
- 7 sites in United States, Canada and 3 more
- Volunteers
- 42 people
- Sponsor
- University Medical Center Groningen
Diabetic Nephropathy
Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria
Study of the efficacy and safety of aliskiren when added to losartan and optimal antihypertensive therapy in patients with hypertension, type 2 diabetes, and kidney disorders to monitor improvement in any of these conditions.
- Trial name
- NCT00097955
- Testing
- aliskiren
- Where
- 12 sites in United States, Canada and 10 more
- Volunteers
- 496 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Nephropathy
Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy
This trial is randomized, placebo-controlled, double blind, double dummy, multi-centre trial. Screening period (4 week) Double blind treatment period (16 weeks)
- Trial name
- NCT01726816
- Testing
- Probucol 250mg/day, Probucol 500mg/day
- Where
- 16 sites in South Korea
- Volunteers
- 126 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2
Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt Nephropathy
This study will assess the optimal renoprotective dose of Aliskiren in hypertensive type 2 diabetes patients with incipient or overt nephropathy
- Trial name
- NCT00464776
- Testing
- Aliskiren
- Where
- Denmark
- Volunteers
- 26 people
- Sponsor
- Novartis
Type 2 Diabetes Mellitus
A Study to Assess Efficacy and Safety of ASP1941 in Diabetic Patients With Renal Impairment
This study is to assess the effect of renal function on the efficacy and safety of ASP1941 in type 2 diabetic patients with mild to moderate renal impairment.
- Trial name
- NCT01316094
- Testing
- ASP1941
- Where
- 8 sites in Japan
- Volunteers
- 165 people
- Sponsor
- Astellas Pharma Inc
Renal Insufficiency, Chronic, Diabetic Nephropathy Type 2
Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy
NephroNet proposes to examine whether combining Spironolactone with maximal RAAS blockade will further reduce urinary protein at one year and whether prolonged therapy (24 months) is able to slow the decline in GFR.
- Trial name
- MRA-ACE (NCT03502031)
- Testing
- Renin-Angiotensin (RAAS) alone, Renin-Angiotensin (RAAS) blockers in combination with Spironolactone
- Where
- 2 sites in United States
- Volunteers
- 72 people
- Sponsor
- James A. Tumlin, MD
Diabetic Nephropathy
Evaluating the Renoprotective Effect of Milk Thistle Extract on Patients With Type II Diabetic Nephropathy
There is considerable evidence that increased blood glucose results in the generation of reactive oxygen species, ultimately leading to increased oxidative stress in a variety of tissues.
- Trial name
- NCT01003236
- Testing
- Milk Thistle extract
- Where
- Iran
- Volunteers
- 60 people
- Sponsor
- Shiraz University of Medical Sciences
Diabetic Nephropathy
The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes
The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2) Whether LY333531 reduces urinary TGF-B, 3) the safety…
- Trial name
- NCT00044148
- Testing
- LY333531
- Where
- 15 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Chromaderm, Inc.
Diabetes Mellitus
Assessment of Serum Magnesium Level with Diabetic Foot Ulceration in Type II Diabetes Associated with Diabetic Nephropathy Patients
Magnesium (Mg), is the fourth most common cation in the body, with an essential role in fundamental biological reactions, whose deficiency provokes biochemical and symptomatic alterations in the human organism.
- Trial name
- NCT06754878
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Assiut University
Diabetic Kidney Disease
Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease
The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due…
- Trial name
- NCT05514548
- Testing
- INV-202
- Where
- 72 sites in United States, Canada and 5 more
- Volunteers
- 265 people
- Sponsor
- Inversago Pharma Inc.
Diabetes Mellitus, Type 2, Kidney Failure, Chronic
Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy
The primary purpose of this study is to test the effectiveness and tolerability of Niaspan® to improve the levels of blood fats ("good" and "bad" cholesterol and triglyceride levels) in people who have kidney damage due to…
- Conditions
- Diabetes Mellitus, Type 2, Kidney Failure, Chronic, Hyperlipidemia
- Trial name
- NCT00108485
- Testing
- Extended release niacin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Miami
Diabetic Nephropathy
Safety and Efficacy Study of Pyridorin in Patients With Nephropathy Due to Type 2 Diabetes
The primary objective of this study is to evaluate the efficacy of two different doses of Pyridorin (150 mg and 300 mg)compared to placebo in retarding the progression of diabetic nephropathy.
- Trial name
- NCT00734253
- Testing
- Pyridoxamine Dihydrochloride
- Where
- United States
- Volunteers
- 317 people
- Sponsor
- NephroGenex, Inc.
Diabetic Nephropathy, Chronic Kidney Disease
The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors
The study objective was to evaluate the safety of paricalcitol capsules and the efficacy of paricalcitol capsules for albuminuria reduction in patients with Chronic Kidney Disease (CKD) who have Type 2 diabetic nephropathy and…
- Trial name
- VITAL (NCT00421733)
- Testing
- Zemplar (paricalcitol ) capsules, Zemplar (paricalcitol) capsules
- Where
- 72 sites in United States, Germany and 8 more
- Volunteers
- 281 people
- Sponsor
- Abbott